Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-gp100:154-162 TCR tumor infiltrating lymphocytes

A preparation of human tumor infiltrating lymphocytes (TILs) isolated from a melanoma patient and engineered to encode a T-cell receptor (TCR) specific for the amino acid 154 through 162 of the melanoma antigen glycoprotein 100 (gp100), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, the autologous anti-gp100:154-162 TCR TILs may recognize and halt the growth of gp100-expressing melanoma cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-gp 100:154-162 TCR TILs
autologous anti-gp100:154-162 TCR gene engineered TILs
autologous anti-gp100:154-162 TCR gene-engineered tumor infiltrating lymphocytes
autologous anti-gp100:154-162 TCR TILs
autologous anti-gp100:154-162 TCR-engineered TILs
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search